Faridoxorubicin
Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα) . Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) [1].
Product Specifications
CAS Number
[1841402-73-0]
Product Name Alternative
AVA-6000
UNSPSC
12352005
Target
FAP
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Smiles
OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC([C@H]6N(CCC6)C([C@@H](C)NC(C7=CC=NC=C7)=O)=O)=O
Molecular Formula
C41H44N4O14
Molecular Weight
816.81
References & Citations
[1]McLaughlin F, et al. AVA6000, a novel precision medicine, targeted to the tumor microenvironment via fibroblast activation protein (FAP) mediated cleavage[J]. Cancer Res, 2022, 82 (12_Supplement) : 1815.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
